Low prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates among Connecticut veterans

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 1, 2012, Pages 582-583

  Fink, Susan L ^a   Martinello, Richard A ^a,b   Campbell, Sheldon M ^a,b   Murray, Thomas S ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c New York   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; UNITED STATES; VETERAN;

AGED; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIAL TYPING TECHNIQUES; CONNECTICUT; FALSE POSITIVE REACTIONS; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PREVALENCE; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN; VANCOMYCIN RESISTANCE; VETERANS;

EID: 84455173115     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05024-11     Document Type: Article

References (19)

1. Agresti A, Coull BA. 1998. Approximate is better than "exact" for interval estimation of binomial proportions. Am. Stat. 52:119-126.
2. Ariza J, et al. 1999. Vancomycin in surgical infections due to methicillinresistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 353:1587-1588. (Pubitemid 29219213)
3. Charles PGP, Ward PB, Johnson PDR, Howden BP, Grayson ML. 2004. Clinical features associated with bacteremia due to heterogeneous vancomycinintermediate Staphylococcus aureus. Clin. Infect. Dis. 38:448-451. (Pubitemid 38200128)
4. Eguia JM, et al. 2005. Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area. Clin. Infect. Dis. 40: 1617-1624. (Pubitemid 40720812)
5. Fridkin SK, et al. 2003. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin. Infect. Dis. 36: 429-439. (Pubitemid 36241308)
6. Horne KC, et al. 2009. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob. Agents Chemother. 53:3447-3452.
7. Howden BP, Ward PB, Johnson PDR, Charles PGP, Grayson ML. 2005. Low-level vancomycin resistance in Staphylococcus aureus-an Australian perspective. Eur. J. Clin. Microbiol. Infect. Dis. 24:100-108. (Pubitemid 40487377)
8. Howden BP, Davies JK, Johnson PDR, Stinear TP, Grayson ML. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23:99-139.
9. Howden BP, et al. 2004. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38:521-528. (Pubitemid 38250962)
10. Leonard SN, Rossi KL, Newton KL, Rybak MJ. 2009. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J. Antimicrob. Chemother. 63:489-492.
11. Liu C, Chambers HF. 2003. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. 47: 3040-3045. (Pubitemid 37229554)
12. Maor Y, et al. 2009. Clinical features of heteroresistant vancomycinintermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J. Infect. Dis. 199:619-624.
13. van Hal SJ, Paterson DL. 2011. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55:405-410.
14. van Hal SJ, et al. 2011. Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates. J. Clin. Microbiol. 49:1489-1494.
15. Voss A, et al. 2007. A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h- GISA). Ann. Clin. Microbiol. Antimicrob. 6:9.
16. Walsh TR, et al. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2439-2444. (Pubitemid 32606216)
17. Wang G, Hindler JF, Ward KW, Bruckner DA. 2006. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 44:3883-3886. (Pubitemid 44737223)
18. Wootton M, et al. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399-403. (Pubitemid 32303403)
19. Yusof A, et al. 2008. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J. Clin. Microbiol. 46:3042-3047.